Navigation Links
Valeant Pharmaceuticals Completes Acquisition of Dow Pharmaceutical Sciences, Inc.
Date:1/3/2009

ALISO VIEJO, Calif., Jan. 2 /PRNewswire-FirstCall/ -- Valeant Pharmaceuticals International (NYSE: VRX) today announced that effective December 31, 2008, the company completed its acquisition of Dow Pharmaceutical Sciences, Inc., a privately held dermatology company that specializes in the development of topical products on a proprietary basis, as well as for pharmaceutical and biotechnology companies.

About Valeant

Valeant Pharmaceuticals International (NYSE: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology and dermatology. More information about Valeant can be found at http://www.valeant.com.

    (Logo: http://www.newscom.com/cgi-bin/prnh/20081125/VALEANTLOGO)

     Contact:
     Laurie W. Little
     Valeant Pharmaceuticals
     949-461-6002

'/>"/>
SOURCE Valeant Pharmaceuticals International
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Valeant to Acquire Dow Pharmaceutical Sciences, Inc. for $285 Million
2. DFB Sells Coria Labs to Valeant Pharmaceuticals
3. Roche Purchases Shares in Tender Offer For Memory Pharmaceuticals Corp.
4. Johnson & Johnson Completes Acquisition of Omrix Biopharmaceuticals, Inc.
5. Webcast Alert: Isis Pharmaceuticals Announces That Abbott Exercised Its Option to Acquire Ibis Biosciences
6. Transcept Pharmaceuticals Announces FDA Acceptance for Review of New Drug Application for Intermezzo(R)
7. Jazz Pharmaceuticals Announces Reduction in Force to Reflect Streamlined Operations
8. Cylene Pharmaceuticals Initiates Phase II Clinical Trial of Quarfloxin (CX-3543) in Patients With Carcinoid/Neuroendocrine Tumors
9. Peregrine Pharmaceuticals Mourns Loss of Chairman Thomas A. Waltz
10. Peregrine Pharmaceuticals Enters Into a Loan Agreement for up to $10 Million
11. AcelRx Pharmaceuticals Reports Positive Results From a Phase 2 Clinical Trial of Sublingual Sufentanil NanoTabs(TM) in Treating Post-Operative Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... May 24, 2013 Vestiage, Inc. ... company focused on science-based research and development, sales ... cosmeceuticals and nutraceuticals, announced today that it is ... for the sale of Reluma Skin Illuminating Facial ... and application by sending an email to info(at)vestiageinc(dot)com ...
(Date:5/23/2013)... 2013 Venaxis, Inc. (Nasdaq:   APPY), an ... FDA clearance and commercializing its rapid, protein biomarker-based appendicitis ... an underwritten public offering of 10,000,000 shares of its ... of its common stock at an exercise price of ... of $1.25 per share and related warrant.  Venaxis has ...
(Date:5/23/2013)... 23, 2013 Patheon Inc ., ... to the global pharmaceutical industry, will host a complimentary ... to Testing” on Tuesday, June 4, 2013 at 11 ... are required to comply with regulations for cleaning validation. ... limited scientific underpinning and little evaluation of risk. ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 PI’s ... wide and provide 15 mm travel range with ... The small dimensions make these new positioners the ... spaces. A vacuum rated version is also available. ... specifications and datasheets can be found at: , ...
Breaking Biology Technology:Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 3Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 4Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 5Venaxis Announces Pricing of Offering of Common Stock and Warrants 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 3Patheon to Present on “Cleaning Validation: Science, Risk and Novel Approaches to Testing” 2Precision Positioning System Uses Miniaturezed Piezo Linear Motor: LPS-24 Linear Stage by PI 2
... 2011 Orexigen ® Therapeutics, Inc. (Nasdaq: ... on the treatment of obesity, today announced that ... Morgan Healthcare Conference. The details are as follows: ... Pacific TimeLocation:  Westin St. Francis Hotel, San Francisco, ...
... Group, Inc. (OTC Bulletin Board: BONU ), ... has received correspondence from KHA Solutions Group following a ... Group, a for-profit entity and a wholly owned subsidiary ... into BioNeutral and its products, BioNeutral may be selected ...
... 2011 Cellular Dynamics International, Inc. (CDI), the world,s ... lines and tissue cells for drug discovery and safety, ... at the 29th Annual JPMorgan Healthcare Conference at 7:30 ... Francis Hotel in San Francisco. Robert Palay, chief executive ...
Cached Biology Technology:Kentucky Hospital Association Solutions Group Outlines Next Steps for BioNeutral Partnership 2Kentucky Hospital Association Solutions Group Outlines Next Steps for BioNeutral Partnership 3
(Date:5/23/2013)... Rollins School of Public Health at Emory University, ... Technology, have received a $4 million grant over ... Emory University (Health and Exposome Research Center: Understanding ... center grant awarded in the United States. ... National Institute of Environmental Health Sciences (NIEHS) of ...
(Date:5/23/2013)... wrapping of genomic DNA around nucleosomes in the ... A team of Ludwig-Maximilians-Universitaet (LMU) in Munich now ... be locally displaced from nucleosomes for transcription. , ... in the cell nucleus, wrapped around disk-shaped particles ... four different histone proteins and accommodating two loops ...
(Date:5/23/2013)... undergo surgery or harsh treatments because science fails ... forms of the disease. Researchers at Case Western ... developing technology that allows patients to safely choose ... or take drastic measures. , The project is ... of biomedical engineering at Case Western Reserve and ...
Breaking Biology News(10 mins):Emory, Georgia Tech receive first human exposome center grant in US 2Emory, Georgia Tech receive first human exposome center grant in US 3Biochemistry: Unspooling DNA from nucleosomal disks 2Using big data to identify prostate cancers and best treatments 2Using big data to identify prostate cancers and best treatments 3
... December 2, 2010 -- Intense, individually tailored dietary treatment ... mortality, according to a new study by researchers at ... just published in the prestigious Journal of the ... months after discharge (11.6 percent) of the control group ...
... year, dengue fever infects as many as 100 million people ... Both diseases are spread by infected female Aedes ... The blood feeding and the egg development are tightly linked ... a team of entomologists at the University of California, Riverside ...
... cited Pfeiffer,s research in biomedical imaging, and in particular ... approach has laid the foundation for applications of this ... to deliver improved image contrast with lower doses of ... from fundamental biophysical investigations to applications in medical imaging ...
Cached Biology News:Personalized diets for elderly after hospitalization decreases mortality rates 2Discovery by UC Riverside entomologists could shrink dengue-spreading mosquito population 2Physicist Franz Pfeiffer receives 2011 Leibniz Prize 2
... SIGNETs BCIP/NBT Chromogen system ... Tetrazolium] chromogen in a single ... reacts in the presence of ... staining with minimal background noise. ...
... BCIP/NBT Chromogen system consists of ... in a single component,solution. The ... the presence of alkaline phosphatase ... with minimal background noise. ,The ...
Mouse monoclonal antibody raised against a partial recombinant VEGFB. NCBI Entrez Gene ID = VEGFB...
... - NH2 is primarily used for the ... cellular proteins for tracing. NH2-Reactive B-Phycoerythrin, a ... (NHS), and can easily make a covalent ... other proteins without any activation process. Filtration ...
Biology Products: